The group's principle activity is to create Cellular Systems Biology(TM) products and services that accelerate the progression of novel therapies from the discovery laboratory through the clinic. The group also provides CellCiphr(TM) cellular models of disease, CellCiphr(TM) cytotoxicity profiling, and CellCiphr(TM) patient sample profiling. The group operates from United States.
